First Trust Capital Management’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

First Trust Capital Management’s Portfolio DMAA Stock Details DMAA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.56M	Hold	786,459	–	–	0.41%	32
2026 Q2	$8.38M	Sell	786,459 -1,456,041	-65%	-$15.4M	0.49%	30
2026 Q1	$23.5M	Hold	2,242,500	–	–	1.23%	18
2025 Q4	$23.3M	Hold	2,242,500	–	–	1.41%	15
2025 Q3	$23M	Hold	2,242,500	–	–	1.49%	15
2025 Q2	$22.9M	Buy	2,242,500 +175,798	+9%	+$1.78M	1.55%	16
2025 Q1	$20.7M	Buy	+2,066,702	New	+$20.7M	1.5%	24

Other funds holding DMAA

Mizuho Securities USA New York $6.3B AUM 30.7% 1-Year Est. Return

Karpus Investment Management Pittsford, New York $3.34B AUM 3.39% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 22.91% 1-Year Est. Return

Crossingbridge Advisors Pleasantville, New York $571M AUM 0.32% 1-Year Est. Return

RLH Capital Great Neck, New York $277M AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Dakota Wealth Management Palm Beach Gardens, Florida $5.38B AUM 27.63% 1-Year Est. Return

Arax Advisory Partners Denver, Colorado $17.7B AUM 20.22% 1-Year Est. Return

First Trust Capital Management's DMAA Position: Q3 2026 in Review

First Trust Capital Management held its Drugs Made In America Acquisition Corp (DMAA) position steady in Q3 2026 at 786,459 shares worth $8.56M. The position accounts for 0.41% of the portfolio, ranked #32.

First Trust Capital Management first reported a position in DMAA in Q1 2025 and has held it in 7 quarters since. The position peaked at $23.5M in Q1 2026. 12 funds tracked by Wall St. Rank hold DMAA as of Q3 2026.

First Trust Capital Management held 786,459 shares of Drugs Made In America Acquisition Corp worth $8.56M as of Q3 2026.
First Trust Capital Management left its Drugs Made In America Acquisition Corp share count unchanged in Q3 2026.
Drugs Made In America Acquisition Corp made up 0.41% of First Trust Capital Management's portfolio in Q3 2026, its #32 holding.
First Trust Capital Management first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and has held it in 7 quarters since.
First Trust Capital Management's Drugs Made In America Acquisition Corp position peaked at $23.5M in Q1 2026.
12 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q3 2026.

Based on First Trust Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.